Astellas Pharma Inc. (4503)

Frankfurt


Symbol		Exchange		Currency
4503	·	Tokyo	·	JPY	Delayed
ALPMY	·	OTC Markets	·	USD	Delayed
4503	·	Frankfurt	·	EUR	Delayed

Currency in EUR

8.3760

+0.4180(+5.25%)

Delayed Data·10:06:55

Fair Value

Unlock Value

Day's Range

8.3460

8.3760

52 wk Range

7.5340

11.6950

4503 Income Statement

Featured here, the Income Statement (earnings report) for Astellas Pharma Inc., showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).

Period Ending:

2016

31/03

2017

31/03

2018

31/03

2019

31/03

2020

31/03

2021

31/03

2022

31/03

2023

31/03

2024

31/03

2025

31/03

Total Revenues

aa.aa

1,249,528

1,296,163

1,518,619

1,603,672

1,912,323

Total Revenues Growth

aa.aa

-3.94%

+3.73%

+17.16%

+5.6%

+19.25%

Cost Of Revenues

aa.aa

246,063

253,009

288,353

292,485

349,206

Gross Profit

aa.aa

1,003,465

1,043,154

1,230,266

1,311,187

1,563,117

Gross Profit Growth

aa.aa

-2.02%

+3.96%

+17.94%

+6.58%

+19.21%

Gross Profit Margin %

aa.aa

80.31%

80.48%

81.01%

81.76%

81.74%

Other Operating Expenses, Total

aa.aa

752,533

825,009

998,614

1,186,581

1,299,577

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-0.54%	+9.63%	+21.04%	+18.82%	+9.52%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	224,489	246,010	276,128	294,187	327,651
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	504,316	548,840	630,272	740,110	843,032
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-35	1,876	53,778	53,464	-7,868

Operating Income

aa.aa

250,932

218,145

231,652

124,606

263,540

Operating Income Growth

aa.aa

-6.19%

-13.07%

+6.19%

-46.21%

+111.5%

EBIT Margin %

aa.aa

20.08%

16.83%

15.25%

7.77%

13.78%

Net Interest Expenses

aa.aa

-1,358

-1,453

2,036

1,428

-7,067

Net Interest Expenses Growth

aa.aa

-8,587.5%

-7%

+240.12%

-29.86%

-594.89%

Interest Expense, Total

aa.aa

-2,118

-2,315

-3,217

-7,423

-13,952

Interest And Investment Income

aa.aa

760

862

5,253

8,851

6,885

Other Non Operating Expenses, Total

aa.aa

-1,782

6,230

-6,561

-5,695

-19,055

EBT, Excl. Unusual Items

aa.aa

247,792

222,922

227,127

120,339

237,418

Gain (Loss) On Sale Of Assets

aa.aa

24,234

212

9,735

1,049

Other Unusual Items, Total

aa.aa

-103,758

-75,798

-85,461

-79,445

-189,191

EBT, Incl. Unusual Items

aa.aa

145,323

156,886

132,361

24,969

31,237

EBT, Incl. Unusual Items Growth

aa.aa

-40.77%

+7.96%

-15.63%

-81.14%

+25.1%

EBT, Incl. Unusual Items Margin

aa.aa

11.63%

12.1%

8.72%

1.56%

1.63%

Income Tax Expense

aa.aa

24,734

32,800

33,647

7,924

-19,510

Net Income to Company

aa.aa

120,589

124,086

98,714

17,045

50,747

Minority Interest

aa.aa

Net Income

aa.aa

120,589

124,086

98,714

17,045

50,747

Net Income Growth

aa.aa

-38.29%

+2.9%

-20.45%

-82.73%

+197.72%

Net Income Margin %

aa.aa

9.65%

9.57%

6.5%

1.06%

2.65%

Preferred Dividend and Other Adjustments

aa.aa

Net Income to Common Excl. Extra Items

aa.aa

120,589

124,086

98,714

17,045

50,747

Basic EPS - Continuing Operations

aa.aa

64.93

67.08

54.24

9.5

28.35

Basic EPS - Continuing Operations Growth

aa.aa

-37.66%

+3.31%

-19.15%

-82.48%

+198.23%

Diluted EPS - Continuing Operations

aa.aa

64.9

67.05

54.09

9.47

28.24

Diluted EPS - Continuing Operations Growth

aa.aa

-37.64%

+3.31%

-19.33%

-82.49%

+198.2%

Basic Weighted Average Shares Outstanding

aa.aa

1,857.13

1,849.71

1,820.02

1,793.28

1,790.21

Diluted Weighted Average Shares Outstanding

aa.aa

1,858.19

1,850.6

1,825.06

1,799.66

1,797.16

Dividend Per Share

aa.aa

Dividend Per Share Growth

aa.aa

+5%

+19.05%

+20%

+16.67%

+5.71%

EBITDA

aa.aa

323,584

297,829

337,390

282,446

462,672

EBITDA Growth

aa.aa

-3.08%

-7.96%

+13.28%

-16.29%

+63.81%

EBITDA Margin %

aa.aa

25.9%

22.98%

22.22%

17.61%

24.19%

EBIT

aa.aa

250,932

218,145

231,652

124,606

263,540

* In Millions of JPY (except for per share items)

NSE 30

4,867.47

+3.88

+0.08%

NSE All Share

132,557.44

+105.70

+0.08%

US 30

44,855.70

+353.5

+0.79%

US 500

6,335.90

+26.3

+0.42%

FTSE 100

9,061.49

+37.68

+0.42%

DAX

24,217.10

+175.20

+0.73%

South Africa Top 40

92,457.00

+866.71

+0.95%

Market Movers

Name	Last	Chg. %	Vol.
Access Holdings	28.50	+3.64%	98.62M
UBA	46.70	0.00%	18.21M
Oando Plc	52.20	+0.77%	16.21M
Guaranty Trust Holding	94.00	+0.21%	12.18M
Lafarge Africa	120.55	-4.33%	8.33M
Dangote Cement	490.00	+0.20%	2.66M
Aradel Holdings	502.00	+0.40%	2.45M

Name	Last	Chg. %	Vol.
Academy Press	7.70	+10.00%	2.13M
Initiates	13.34	+9.98%	2.11M
Ikeja	21.000	+9.95%	762.28K
Nigerian Enamelware PLC	24.55	+9.84%	239.53K
Nahco	117.000	+9.65%	2.53M
International Energy Insurance	2.38	+8.18%	3.16M
Cornerst	4.50	+7.40%	5.15M

Name	Last	Chg. %	Vol.
Austin Laz	2.34	-10.00%	289.11K
Tripple Gee and Co	3.89	-9.95%	159.73K
Omatek Ventures	1.30	-9.72%	4.30M
Daarcomm	0.75	-9.64%	4.73M
Guinea Insurance PLC	0.90	-9.09%	9.08M
Multverse	9.00	-9.09%	322.58K
Redstarex	11.75	-9.06%	434.41K

Trending Stocks

Name	Last	Chg. %	Vol.
Aradel Holdings	502.00	+0.40%	2.45M
Guaranty Trust Holding	94.00	+0.21%	12.18M
Ellah Lakes	9.21	-6.97%	61.12M
Lafarge Africa	120.55	-4.33%	8.33M
Dangote Sugar	60.00	+6.95%	6.08M

Most Undervalued Stocks

Name	Last	Upside	Fair Value
Aaaaaa	66.00	+22.27%	80.70
Aaaaaaa Aaa	400.00	+10.02%	440.08

See full list

Install Our AppScan QR code to install app

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers

Popular Searches

Please try another search

Astellas Pharma Inc. (4503)

4503 Income Statement

Trending Stocks